Free tool
FAERS Monitor: Tivdak
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761208 or its brand name (Tivdak, Tisotumab Vedotin-Tftv). Reports on generic versions are filed under their own applications.
Reports
971
Serious
609
63% of reports
Hospitalization
237
Death reported
81
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- malignant neoplasm progression80
- neuropathy peripheral79
- nausea66
- dry eye55
- conjunctivitis52
- rash47
- off label use42
- death40
- diarrhoea40
- anaemia35
- fatigue34
- eye disorder31
- epistaxis29
- vomiting26
- weight decreased26
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 6 |
| 2020 | 14 |
| 2021 | 24 |
| 2022 | 172 |
| 2023 | 186 |
| 2024 | 182 |
| 2025 | 232 |
| 2026 | 155 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,188 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| conjunctivitisSignal | 52 | 60.9 | 46.7 | 2,998 |
| dry eyeSignal | 55 | 23.9 | 18.5 | 1,185 |
| eye disorderSignal | 31 | 20.4 | 14.5 | 554 |
| neuropathy peripheralSignal | 79 | 18.0 | 14.6 | 1,256 |
| malignant neoplasm progressionSignal | 80 | 16.9 | 13.7 | 1,188 |
| epistaxisSignal | 29 | 8.4 | 5.9 | 182 |
| anaemiaSignal | 35 | 4.0 | 2.9 | 76 |
| rashSignal | 47 | 2.3 | 1.8 | 35 |
| weight decreasedSignal | 26 | 2.0 | 1.4 | 13 |
| nausea | 66 | 1.8 | 1.4 | 24 |
| diarrhoea | 40 | 1.3 | 1.0 | 3 |
| vomiting | 26 | 1.2 | 0.8 | 1 |
| off label use | 42 | 1.0 | 0.8 | 0 |
| death | 40 | 1.0 | 0.7 | 0 |
| fatigue | 34 | 0.9 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.